Logo.png
GRI Bio Participates in Virtual Investor KOL Connect Segment
September 18, 2024 09:00 ET | GRI Bio, Inc.
Albert Agro, PhD, CMO of GRI Bio recently participated in a Virtual Investor KOL Connect segment with prominent key opinion leader in Idiopathic Pulmonary Fibrosis (IPF) – Dr. Helen Parfrey,...
Logo.png
GRI Bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference
September 05, 2024 08:45 ET | GRI Bio, Inc.
LA JOLLA, CA, Sept. 05, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell...
Logo.png
GRI Bio to Present at the 2024 European Respiratory Congress
September 04, 2024 08:45 ET | GRI Bio, Inc.
LA JOLLA, CA, Sept. 04, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell...
Logo.png
GRI Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update
August 14, 2024 08:05 ET | GRI Bio, Inc.
Company focused on execution of lead program GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (IPF) GRI-0621 interim data readout of Phase 2a biomarker study on track for Q4 2024 and...
Logo.png
GRI Bio (NASDAQ: GRI) to Participate in the Virtual Investor Lunch Break Series
July 15, 2024 09:05 ET | GRI Bio, Inc.
Live video webcast on Wednesday, July 17th at 12:00 PM ET LA JOLLA, CA, July 15, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio,” “we,” “our,” or the “Company”), a...
Logo.png
GRI Bio (NASDAQ: GRI) Participates in Virtual Investor “What This Means” Segment
July 11, 2024 09:20 ET | GRI Bio, Inc.
Marc Hertz, PhD, CEO of GRI Bio underscores importance of the interim data from their ongoing Phase 2a biomarker study for Idiopathic Pulmonary Fibrosis (IPF) LA JOLLA, CA, July 11, 2024 (GLOBE...
Logo.png
GRI Bio Regains Compliance with Nasdaq
July 08, 2024 09:05 ET | GRI Bio, Inc.
LA JOLLA, CA, July 08, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell...
Logo.png
GRI Bio Announces Publication of Positive Preclinical Data from Lead Program GRI-0621 in the American Journal of Respiratory and Critical Care Medicine
July 02, 2024 09:05 ET | GRI Bio, Inc.
Data demonstrates that NKT cells are activated in airways in IPF patients and inhibition of type 1 invariant NKT (iNKT) cell activity can ameliorate bleomycin-induced pulmonary fibrosis in mice ...
Logo.png
GRI Bio to Present at the 8th Annual IPF Summit
July 01, 2024 08:45 ET | GRI Bio, Inc.
LA JOLLA, CA, July 01, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell...
Logo.png
GRI Bio Announces Closing of $4.0 Million Public Offering
June 28, 2024 16:05 ET | GRI Bio, Inc.
LA JOLLA, CA, June 28, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell...